DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
PTC299 is an investigational drug.
There have been 7 clinical trials for PTC299. The most recent clinical trial was a Phase 1 trial, which was initiated on June 30th 2020.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Neurofibroma, and Leukemia, Myeloid. The leading clinical trial sponsors are PTC Therapeutics, National Cancer Institute (NCI), and United States Department of Defense.
There are nine US patents protecting this investigational drug and sixty international patents.
Recent Clinical Trials for PTC299
|A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)||PTC Therapeutics||Phase 2/Phase 3|
|Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias||PTC Therapeutics||Phase 1|
|PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for PTC299
Top clinical trial sponsors for PTC299
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PTC299||Start Trial||Carboline derivatives useful in the inhibition of angiogenesis||PTC Therapeutics, Inc. (South Plainfield, NJ)||Start Trial|
|PTC299||Start Trial||Carboline derivatives useful in the treatment of cancer||PTC Therapeutics, Inc. (South Planfield, NJ)||Start Trial|
|PTC299||Start Trial||Administration of carboline derivatives useful in the treatment of cancer and other diseases||PTC Therapeutics, Inc. (South Plainfield, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|